Cynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, has received regulatory and ethics approval to commence its Phase 2 clinical trial at clinical centres in Turkey | ASX announcement: https://app.sharelinktechnologies.com/announcement/asx/e0fa6ac7f7a6ddf39eef8d4299365c12 #shorts
ASR
0.002
100%
MHK
0.17
-54.1%
WEL
0.002
100%
XPN
0.007
-36.4%
ALM
0.006
50%
ECT
0.002
-33.3%
IS3
0.012
33.3%
SER
0.005
-28.6%
NVQ
0.049
28.9%
CHM
0.003
-25%
PPK
0.71
25.7%
MEM
0.003
-25%
DDT
0.005
25%
FLC
0.044
-24.1%
I88
0.155
24%
CTT
0.27
-20.6%
AAU
0.006
20%
3DP
0.046
-19.3%
AVE
0.006
20%
IR1
0.09
-18.2%
BDG
0.084
20%
GRE
0.066
-17.5%
C1X
0.078
20%
MVP
0.57
-16.8%
FAU
0.006
20%
AQC
0.01
-16.7%
FBR
0.006
20%
ASE
0.021
-16%
X2M
0.019
18.8%
MQR
0.011
-15.4%
XRG
0.032
18.5%
NYM
0.039
-15.2%
SRL
1.225
16.7%
LML
0.006
-14.3%
TMS
0.007
16.7%
MAG
0.044
-13.7%
VKA
0.007
16.7%
DUB
0.019
-13.6%
DRO
3.68
16.1%
JNS
0.13
-13.3%
